JP2006045217A - Zinc-containing composition for oral administration - Google Patents
Zinc-containing composition for oral administration Download PDFInfo
- Publication number
- JP2006045217A JP2006045217A JP2005196925A JP2005196925A JP2006045217A JP 2006045217 A JP2006045217 A JP 2006045217A JP 2005196925 A JP2005196925 A JP 2005196925A JP 2005196925 A JP2005196925 A JP 2005196925A JP 2006045217 A JP2006045217 A JP 2006045217A
- Authority
- JP
- Japan
- Prior art keywords
- zinc
- fatty acid
- oral administration
- composition
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 239000011701 zinc Substances 0.000 title abstract description 13
- 229910052725 zinc Inorganic materials 0.000 title abstract description 13
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 title abstract description 12
- -1 fatty acid ester Chemical class 0.000 claims abstract description 27
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 24
- 239000000194 fatty acid Substances 0.000 claims abstract description 24
- 229930195729 fatty acid Natural products 0.000 claims abstract description 24
- 229920000223 polyglycerol Polymers 0.000 claims abstract description 18
- 150000003752 zinc compounds Chemical class 0.000 claims abstract description 12
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 9
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 9
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 9
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 9
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims abstract description 6
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims abstract description 3
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims abstract description 3
- 239000011667 zinc carbonate Substances 0.000 claims abstract description 3
- 235000004416 zinc carbonate Nutrition 0.000 claims abstract description 3
- 229910000010 zinc carbonate Inorganic materials 0.000 claims abstract description 3
- 229940043825 zinc carbonate Drugs 0.000 claims abstract description 3
- 239000011592 zinc chloride Substances 0.000 claims abstract description 3
- 235000005074 zinc chloride Nutrition 0.000 claims abstract description 3
- 229960001939 zinc chloride Drugs 0.000 claims abstract description 3
- 239000011746 zinc citrate Substances 0.000 claims abstract description 3
- 235000006076 zinc citrate Nutrition 0.000 claims abstract description 3
- 229940068475 zinc citrate Drugs 0.000 claims abstract description 3
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 claims abstract description 3
- 229910000165 zinc phosphate Inorganic materials 0.000 claims abstract description 3
- 229940077935 zinc phosphate Drugs 0.000 claims abstract description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims abstract description 3
- 229960001763 zinc sulfate Drugs 0.000 claims abstract description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims abstract description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 16
- 150000002148 esters Chemical group 0.000 claims description 11
- 235000019640 taste Nutrition 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 4
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 238000006116 polymerization reaction Methods 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 abstract description 22
- 235000019606 astringent taste Nutrition 0.000 abstract description 12
- 235000011187 glycerol Nutrition 0.000 abstract description 7
- 239000003814 drug Substances 0.000 abstract description 6
- 206010013911 Dysgeusia Diseases 0.000 abstract description 3
- 125000004185 ester group Chemical group 0.000 abstract 1
- 150000002314 glycerols Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 230000000379 polymerizing effect Effects 0.000 abstract 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 239000008213 purified water Substances 0.000 description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 235000015165 citric acid Nutrition 0.000 description 10
- 239000002253 acid Substances 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 5
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 4
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000008369 fruit flavor Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 4
- 150000007522 mineralic acids Chemical class 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 230000004845 protein aggregation Effects 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 4
- UIERGBJEBXXIGO-UHFFFAOYSA-N thiamine mononitrate Chemical compound [O-][N+]([O-])=O.CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N UIERGBJEBXXIGO-UHFFFAOYSA-N 0.000 description 4
- 239000000811 xylitol Substances 0.000 description 4
- 235000010447 xylitol Nutrition 0.000 description 4
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 4
- 229960002675 xylitol Drugs 0.000 description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 3
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 3
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
- 241000544066 Stevia Species 0.000 description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 3
- 235000010358 acesulfame potassium Nutrition 0.000 description 3
- 229960004998 acesulfame potassium Drugs 0.000 description 3
- 239000000619 acesulfame-K Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 229940093915 gynecological organic acid Drugs 0.000 description 3
- 239000001630 malic acid Substances 0.000 description 3
- 235000011090 malic acid Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 235000005985 organic acids Nutrition 0.000 description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 229950001574 riboflavin phosphate Drugs 0.000 description 3
- 230000001953 sensory effect Effects 0.000 description 3
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 3
- 239000004299 sodium benzoate Substances 0.000 description 3
- 235000010234 sodium benzoate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 235000018553 tannin Nutrition 0.000 description 3
- 239000001648 tannin Substances 0.000 description 3
- 229920001864 tannin Polymers 0.000 description 3
- 229940093609 tricaprylin Drugs 0.000 description 3
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- LBIBJGZCAVJMOV-UHFFFAOYSA-N 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol pyridine-3-carboxamide hydrochloride Chemical compound Cl.NC(=O)c1cccnc1.Cc1ncc(CO)c(CO)c1O LBIBJGZCAVJMOV-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000002280 amphoteric surfactant Substances 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 2
- 239000001527 calcium lactate Substances 0.000 description 2
- 235000011086 calcium lactate Nutrition 0.000 description 2
- 229960002401 calcium lactate Drugs 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 239000004359 castor oil Substances 0.000 description 2
- 235000019438 castor oil Nutrition 0.000 description 2
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
- 239000012676 herbal extract Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229960001983 magnesium aspartate Drugs 0.000 description 2
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 235000019192 riboflavin Nutrition 0.000 description 2
- 239000002151 riboflavin Substances 0.000 description 2
- 229940109850 royal jelly Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000002639 sodium chloride Nutrition 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940042585 tocopherol acetate Drugs 0.000 description 2
- 239000009538 yokuinin Substances 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- WTAYIFXKJBMZLY-XZABIIKCSA-N OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O Chemical compound OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.OCC(O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O WTAYIFXKJBMZLY-XZABIIKCSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960003589 arginine hydrochloride Drugs 0.000 description 1
- PLKYGPRDCKGEJH-UHFFFAOYSA-N azane;2-hydroxypropane-1,2,3-tricarboxylic acid;iron Chemical compound N.[Fe].OC(=O)CC(O)(C(O)=O)CC(O)=O PLKYGPRDCKGEJH-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- PHIQHXFUZVPYII-UHFFFAOYSA-N carnitine Chemical compound C[N+](C)(C)CC(O)CC([O-])=O PHIQHXFUZVPYII-UHFFFAOYSA-N 0.000 description 1
- 229960000678 carnitine chloride Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229960002104 cyanocobalamin Drugs 0.000 description 1
- 235000000639 cyanocobalamin Nutrition 0.000 description 1
- 239000011666 cyanocobalamin Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- WPUMTJGUQUYPIV-JIZZDEOASA-L disodium (S)-malate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](O)CC([O-])=O WPUMTJGUQUYPIV-JIZZDEOASA-L 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- VZCCETWTMQHEPK-UHFFFAOYSA-N gamma-Linolensaeure Natural products CCCCCC=CCC=CCC=CCCCCC(O)=O VZCCETWTMQHEPK-UHFFFAOYSA-N 0.000 description 1
- FODTZLFLDFKIQH-FSVGXZBPSA-N gamma-Oryzanol (TN) Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)O[C@@H]2C([C@@H]3CC[C@H]4[C@]5(C)CC[C@@H]([C@@]5(C)CC[C@@]54C[C@@]53CC2)[C@H](C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-FSVGXZBPSA-N 0.000 description 1
- VZCCETWTMQHEPK-QNEBEIHSSA-N gamma-linolenic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/CCCCC(O)=O VZCCETWTMQHEPK-QNEBEIHSSA-N 0.000 description 1
- 235000020664 gamma-linolenic acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229960002733 gamolenic acid Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 150000004667 medium chain fatty acids Chemical class 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 229940101267 panthenol Drugs 0.000 description 1
- 235000020957 pantothenol Nutrition 0.000 description 1
- 239000011619 pantothenol Substances 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000019265 sodium DL-malate Nutrition 0.000 description 1
- 239000001394 sodium malate Substances 0.000 description 1
- WTWSHHITWMVLBX-DKWTVANSSA-M sodium;(2s)-2-aminobutanedioate;hydron Chemical compound [Na+].[O-]C(=O)[C@@H](N)CC(O)=O WTWSHHITWMVLBX-DKWTVANSSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
Images
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本発明は、亜鉛化合物の不快な味を低減し、服用感を良好にした経口投与組成物に関する。 The present invention relates to an orally administered composition that reduces the unpleasant taste of zinc compounds and improves the feeling of taking.
亜鉛含有経口投与組成物は亜鉛イオンに由来する不快な味のため飲みにくいものであった。この味は、タンニンやミョウバンなどのタンパクと結合する収斂剤を口にしたときの味（収斂味）と共通のものである。これまで、亜鉛化合物を含有する薬剤や食品の不快な味を改善するため、アルキルジメチルベタインなどのベタイン型両性界面活性剤を配合する技術が開示されている（特許文献１）。しかしながら、これらの両性界面活性剤では亜鉛イオンに由来する不快な味を改善する効果は充分でなかった。 The composition containing orally containing zinc is difficult to drink due to an unpleasant taste derived from zinc ions. This taste is the same as the taste when using an astringent that binds to proteins such as tannin and alum. Until now, in order to improve the unpleasant taste of drugs and foods containing zinc compounds, a technique of blending a betaine-type amphoteric surfactant such as alkyldimethylbetaine has been disclosed (Patent Document 1). However, these amphoteric surfactants have not been sufficiently effective in improving the unpleasant taste derived from zinc ions.
本発明の目的は、亜鉛イオンに由来する収斂味を低減し、飲みやすく、しかも不快な後味が残らない亜鉛含有経口投与組成物を提供することである。 An object of the present invention is to provide a zinc-containing oral administration composition that reduces the astringent taste derived from zinc ions, is easy to drink, and does not leave an unpleasant aftertaste.
上記課題を解決するために、本発明者らは、鋭意検討を重ねた結果、亜鉛化合物にポリグリセリン脂肪酸エステルを配合すると、亜鉛イオンによるタンパクの凝集（収斂性）が低減し、収斂味が改善されることを見出し、本発明を完成した。 In order to solve the above-mentioned problems, the present inventors have made extensive studies. As a result, when a polyglycerol fatty acid ester is blended with a zinc compound, protein aggregation (convergence) due to zinc ions is reduced, and astringency is improved. As a result, the present invention has been completed.
すなわち、本発明は、亜鉛化合物およびポリグリセリン脂肪酸エステルを含有することを特徴とする経口投与組成物である。 That is, the present invention is an orally administered composition comprising a zinc compound and a polyglycerol fatty acid ester.
本発明における亜鉛化合物とは、亜鉛を含む塩であり、塩を形成する酸は無毒性であれば有機酸又は無機酸のどちらでもかまわず、有機酸としては例えば、乳酸、グルコン酸、クエン酸、リンゴ酸、酒石酸等の有機酸を、また無機酸としては、例えば、硫酸、炭酸、塩酸、リン酸、硝酸等を挙げることができる。好ましい亜鉛化合物としては、例えば、グルコン酸亜鉛、硫酸亜鉛、クエン酸亜鉛、炭酸亜鉛、塩化亜鉛、リン酸亜鉛などが挙げられる。これらは、単独で配合してもよく、２種以上を組み合わせて配合してもよい。 The zinc compound in the present invention is a salt containing zinc, and the acid forming the salt may be either an organic acid or an inorganic acid as long as it is non-toxic. Examples of the organic acid include lactic acid, gluconic acid, and citric acid. Organic acids such as malic acid and tartaric acid, and inorganic acids include sulfuric acid, carbonic acid, hydrochloric acid, phosphoric acid, nitric acid and the like. Preferred zinc compounds include, for example, zinc gluconate, zinc sulfate, zinc citrate, zinc carbonate, zinc chloride, zinc phosphate and the like. These may be blended singly or in combination of two or more.
亜鉛化合物の配合量は、これを配合する亜鉛含有経口投与組成物の使用目的により異なる。栄養摂取量の面からは、亜鉛イオンに換算して、１日当たり１〜５０ｍｇが好ましく、１日に１００ｍｌの内服液剤として摂取する場合、その亜鉛イオン濃度は、０.００１〜０.０５Ｗ／Ｖ％である。 The compounding quantity of a zinc compound changes with the intended purposes of the zinc containing oral administration composition which mix | blends this. In terms of nutrient intake, 1 to 50 mg per day is preferable in terms of zinc ions, and when taken as a 100 ml oral solution per day, the zinc ion concentration is 0.001 to 0.05 W / V. %.
本発明におけるポリグリセリン脂肪酸エステルとは、４〜２０個のグリセリンが重合したポリグリセリンと炭素数８〜２０個の脂肪酸を縮合したエステルであって、ＨＬＢが１２以上のものである。具体的には、デカグリセリンモノミリスチン酸エステル、ヘキサグリセリンモノミリスチン酸エステル、デカグリセリンモノラウリン酸エステル、ヘキサグリセリンモノラウリン酸エステル、デカグリセリンモノステアリン酸エステル、ヘキサグリセリンモノステアリン酸エステル、デカグリセリンモノカプリル酸エステル、デカグリセリンモノオレイン酸エステル、ヘキサグリセリンモノオレイン酸エステル、デカグリセリンモノリノレン酸エステルなどが挙げられ、その中でもデカグリセリンモノミリスチン酸エステル、デカグリセリンモノステアリン酸エステル、デカグリセリンモノラウリン酸エステルが好ましい。 The polyglycerol fatty acid ester in the present invention is an ester obtained by condensing polyglycerol obtained by polymerization of 4 to 20 glycerol and a fatty acid having 8 to 20 carbon atoms, and has an HLB of 12 or more. Specifically, decaglycerin monomyristic acid ester, hexaglycerin monomyristic acid ester, decaglycerin monolauric acid ester, hexaglycerin monolauric acid ester, decaglycerin monostearic acid ester, hexaglycerin monostearic acid ester, decaglycerin monocaprylic acid Ester, decaglycerin monooleate, hexaglycerin monooleate, decaglycerin monolinolenic acid ester, etc. Among them, decaglycerin monomyristic acid ester, decaglycerin monostearic acid ester, decaglycerin monolauric acid ester are preferable. .
本発明の亜鉛含有経口投与組成物において、ポリグリセリン脂肪酸エステルの配合量は、亜鉛化合物を亜鉛イオンに換算したとき、その亜鉛イオン１質量部に対し０.１質量部以上であり、好ましくは０.５〜２０００質量部、さらに好ましくは２.５〜１０００質量部である。 In the zinc-containing oral administration composition of the present invention, the amount of polyglycerin fatty acid ester is 0.1 parts by mass or more, preferably 0 with respect to 1 part by mass of zinc ions when the zinc compound is converted into zinc ions. It is 0.5-2000 mass parts, More preferably, it is 2.5-1000 mass parts.
本発明の亜鉛含有経口投与組成物を内服液剤とする場合には、防腐性および風味等を考慮してそのｐＨを２.５〜７.０、好ましくは３.０〜５.５とする。この内服液剤のｐＨは、例えば、クエン酸、リンゴ酸、フマル酸、酒石酸、乳酸、コハク酸などの有機酸、これら有機酸の塩、リン酸、塩酸などの無機酸、水酸化ナトリウムなどの無機塩基を添加して調整することができる。 When the zinc-containing composition for oral administration of the present invention is used as an internal solution, the pH is adjusted to 2.5 to 7.0, preferably 3.0 to 5.5 in consideration of preservability and flavor. The pH of the internal solution is, for example, organic acids such as citric acid, malic acid, fumaric acid, tartaric acid, lactic acid, succinic acid, salts of these organic acids, inorganic acids such as phosphoric acid and hydrochloric acid, inorganic acids such as sodium hydroxide, etc. It can be adjusted by adding a base.
本発明の亜鉛含有経口投与組成物には、ビタミン類、ミネラル類、アミノ酸類、生薬、生薬抽出物、カフェイン、ローヤルゼリーなどを本発明の効果を損なわない範囲で適宜に配合できる。また、必要に応じて界面活性剤、抗酸化剤、着色剤、香料、矯味剤、溶解補助剤、保存剤および甘味料などの添加物を本発明の効果を損なわない範囲で適宜に配合できる。 Vitamins, minerals, amino acids, herbal medicines, herbal extracts, caffeine, royal jelly, and the like can be appropriately blended in the zinc-containing oral administration composition of the present invention as long as the effects of the present invention are not impaired. In addition, additives such as surfactants, antioxidants, colorants, fragrances, flavoring agents, solubilizers, preservatives, and sweeteners can be appropriately blended as necessary so long as the effects of the present invention are not impaired.
なお、ポリグリセリン脂肪酸エステルは低温保存時、溶解度が低下し、沈澱や浮遊物を生じ易い。そのため、生薬又は生薬抽出物などの有効成分を配合する場合には、これら有効成分を安定に溶解させるために、ポリオキシエチレン系非イオン性界面活性剤および油成分を配合することが好ましい。 Polyglycerin fatty acid esters have low solubility during storage at low temperatures, and are liable to cause precipitation and floating matters. Therefore, when blending active ingredients such as herbal medicine or herbal extract, it is preferable to blend a polyoxyethylene nonionic surfactant and an oil component in order to dissolve these active ingredients stably.
上記油成分としては、ビタミンＥ、ビタミンＥの誘導体（例えば酢酸、コハク酸等のエステル）、ビタミンＡ、ビタミンＤ、ビタミンＫ、γ−オリザノール、大豆油、中鎖脂肪酸トリグリセリド、γ−リノレン酸等のトリグリセリン脂肪酸エステル等を挙げることができる。これらは１種又は２種以上を混合して用いることができる。生薬又は生薬抽出物などの有効成分を安定に溶解するためには、油成分の配合量をポリグリセリン脂肪酸エステル１質量部に対して０.７質量部以下とすることが望ましい。 Examples of the oil component include vitamin E, derivatives of vitamin E (for example, esters such as acetic acid and succinic acid), vitamin A, vitamin D, vitamin K, γ-oryzanol, soybean oil, medium chain fatty acid triglyceride, γ-linolenic acid, etc. And triglycerin fatty acid esters. These may be used alone or in combination of two or more. In order to dissolve an active ingredient such as a crude drug or a crude drug extract stably, the amount of the oil component is preferably 0.7 parts by mass or less with respect to 1 part by mass of the polyglycerol fatty acid ester.
本発明の亜鉛含有経口投与組成物を調製する方法は特に限定されるものではない。内服液剤とする場合には、通常、各成分を適量の精製水で溶解した後、ｐＨを調整し、残りの精製水を加えて容量調整し、必要に応じて濾過、滅菌処理することにより目的の亜鉛含有経口投与組成物を得ることができる。 The method for preparing the zinc-containing oral administration composition of the present invention is not particularly limited. When using it as an internal solution, the purpose is usually to dissolve each component with an appropriate amount of purified water, adjust the pH, adjust the volume by adding the remaining purified water, and filter and sterilize as necessary. A zinc-containing composition for oral administration can be obtained.
以下に実施例及び試験例を挙げ、本発明をより詳しく説明する。 Hereinafter, the present invention will be described in more detail with reference to examples and test examples.
実施例１
グルコン酸亜鉛 ０.０８ｇ
ポリグリセリン脂肪酸エステル ０.２０ｇ
酢酸トコフェロール ０.１０ｇ
硝酸チアミン ０.０１ｇ
リン酸リボフラビンナトリウム ０.０１ｇ
塩酸ピリドキシン ０.０１ｇ
アスコルビン酸 １.００ｇ
アミノエチルスルホン酸 ２.００ｇ
キシリトール ４.００ｇ
トレハロース ５.００ｇ
エリスリトール ５.００ｇ
クエン酸 ０.８０ｇ
クエン酸ナトリウム 適量
安息香酸ナトリウム ０.０６ｇ
グリセリン ０.２０ｇ
ミックスフルーツフレーバー ０.１０ｇ
上記成分を精製水に溶解した後、ｐＨを３.０に調整し、精製水を加えて全量を１００ｍＬとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を８０℃で２５分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 1
Zinc gluconate 0.08g
Polyglycerol fatty acid ester 0.20 g
Tocopherol acetate 0.10g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.01 g
0.01 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Aminoethylsulfonic acid 2.00g
Xylitol 4.00g
Trehalose 5.00g
Erythritol 5.00g
Citric acid 0.80 g
Sodium citrate appropriate amount Sodium benzoate 0.06g
Glycerin 0.20g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.0, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.
実施例２
グルコン酸亜鉛 ０.０４ｇ
ポリグリセリン脂肪酸エステル ０.２０ｇ
アルギン酸プロピレングリコール ０.０５ｇ
酢酸トコフェロール ０.１０ｇ
グルコン酸カルシウム ２.００ｇ
アスパラギン酸マグネシウム １.００ｇ
硝酸チアミン ０.０１ｇ
リボフラビン ０.０１ｇ
塩酸ピリドキシン ０.１０ｇ
アスコルビン酸 １.００ｇ
アミノエチルスルホン酸 １.００ｇ
ソルビトール ４.００ｇ
トレハロース ５.００ｇ
キシリトール ４.００ｇ
ステビア抽出物 ０.０３ｇ
アセスルファムカリウム ０.０３ｇ
リンゴ酸 ０.１０ｇ
クエン酸 ０.４０ｇ
クエン酸ナトリウム 適量
安息香酸 ０.０６ｇ
パラオキシ安息香酸ブチル ０.００６ｇ
パラオキシ安息香酸プロピル ０.００６ｇ
グリセリン ０.２０ｇ
アップルフレーバー ０.１０ｇ
上記成分を精製水に溶解した後、ｐＨを４.０に調整し、精製水を加えて全量を１００ｍＬとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を８０℃で２５分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 2
Zinc gluconate 0.04g
Polyglycerol fatty acid ester 0.20 g
Propylene glycol alginate 0.05g
Tocopherol acetate 0.10g
Calcium gluconate 2.00g
Magnesium aspartate 1.00 g
0.01 g of thiamine nitrate
Riboflavin 0.01g
0.10 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Aminoethylsulfonic acid 1.00g
Sorbitol 4.00g
Trehalose 5.00g
Xylitol 4.00g
Stevia extract 0.03g
Acesulfame potassium 0.03g
Malic acid 0.10g
Citric acid 0.40g
Sodium citrate appropriate amount Benzoic acid 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
Glycerin 0.20g
Apple flavor 0.10g
After dissolving the above components in purified water, the pH was adjusted to 4.0, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.
実施例３
グルコン酸亜鉛 ０.０８ｇ
ポリグリセリン脂肪酸エステル ０.２０ｇ
ショ糖脂肪酸エステル ０.１０ｇ
リボフラビン ０.０１ｇ
塩酸ピリドキシン ０.０１ｇ
アスコルビン酸 １.００ｇ
シアノコバラミン １２０μｇ
パンテノール ０.０１ｇ
ニコチン酸アミド ０.０５ｇ
アミノエチルスルホン酸 １.００ｇ
ソルビトール ５.００ｇ
トレハロース ２.００ｇ
マルチトール ２.００ｇ
クエン酸 ０.４０ｇ
リンゴ酸ナトリウム 適量
安息香酸 ０.０６ｇ
パラオキシ安息香酸ブチル ０.００６ｇ
パラオキシ安息香酸プロピル ０.００６ｇ
トリカプリリン ０.０５ｇ
グリセリン ０.２０ｇ
ミックスフルーツフレーバー ０.１０ｇ
上記成分を精製水に溶解した後、ｐＨを４.５に調整し、精製水を加えて全量を１００ｍＬとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を８０℃で２５分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 3
Zinc gluconate 0.08g
Polyglycerol fatty acid ester 0.20 g
Sucrose fatty acid ester 0.10g
Riboflavin 0.01g
0.01 g of pyridoxine hydrochloride
Ascorbic acid 1.00g
Cyanocobalamin 120μg
Panthenol 0.01g
Nicotinamide 0.05g
Aminoethylsulfonic acid 1.00g
Sorbitol 5.00g
Trehalose 2.00g
Maltitol 2.00g
Citric acid 0.40g
Sodium malate appropriate amount Benzoic acid 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
Tricaprylin 0.05g
Glycerin 0.20g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 4.5, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.
実施例４
グルコン酸亜鉛 ０.０１ｇ
ポリグリセリン脂肪酸エステル ０.２０ｇ
ポリオキシエチレン硬化ヒマシ油 ０.１０ｇ
トリカプリリン ０.０５ｇ
乳酸カルシウム ０.３０ｇ
塩化マグネシウム ０.０６ｇ
クエン酸鉄アンモニウム ０.０５ｇ
硝酸チアミン ０.０１ｇ
リン酸リボフラビンナトリウム ０.０１ｇ
塩酸ピリドキシン ０.０１ｇ
ニコチン酸アミド ０.１０ｇ
無水カフェイン ０.１０ｇ
アミノエチルスルホン酸 ２.００ｇ
塩化カルニチン ０.２０ｇ
アルギニン塩酸塩 ０.２０ｇ
ヨクイニン流エキス ２.００ｍＬ
ブドウ糖 ５.００ｇ
難消化性デキストリン ４.００ｇ
エリスリトール ５.００ｇ
キシリトール ２.００ｇ
ステビア抽出物 ０.０２ｇ
アセスルファムカリウム ０.０３ｇ
スクラロース ０.０５ｇ
クエン酸 ０.８０ｇ
クエン酸ナトリウム 適量
安息香酸ナトリウム ０.０６ｇ
パラオキシ安息香酸ブチル ０.００６ｇ
パラオキシ安息香酸プロピル ０.００６ｇ
グリセリン ０.２０ｇ
ミックスフルーツフレーバー ０.１０ｇ
上記成分を精製水に溶解した後、ｐＨを３.５に調整し、精製水を加え全量を１００ｍＬとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を８０℃で２５分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 4
Zinc gluconate 0.01g
Polyglycerol fatty acid ester 0.20 g
Polyoxyethylene hydrogenated castor oil 0.10g
Tricaprylin 0.05g
Calcium lactate 0.30g
Magnesium chloride 0.06g
0.05 g of ammonium iron citrate
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.01 g
0.01 g of pyridoxine hydrochloride
Nicotinamide 0.10g
Anhydrous caffeine 0.10g
Aminoethylsulfonic acid 2.00g
Carnitine chloride 0.20g
Arginine hydrochloride 0.20g
Yokuinin style extract 2.00mL
Glucose 5.00g
Indigestible dextrin 4.00 g
Erythritol 5.00g
Xylitol 2.00g
Stevia extract 0.02g
Acesulfame potassium 0.03g
Sucralose 0.05g
Citric acid 0.80 g
Sodium citrate appropriate amount Sodium benzoate 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
Glycerin 0.20g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.5, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.
実施例５
グルコン酸亜鉛 ０.０８ｇ
ポリグリセリン脂肪酸エステル ０.２０ｇ
ポリオキシエチレン硬化ヒマシ油 ０.１０ｇ
トリカプリリン ０.０５ｇ
グルコン酸カルシウム ２.００ｇ
乳酸カルシウム １.００ｇ
アスパラギン酸ナトリウム ０.１０ｇ
アスパラギン酸マグネシウム １.００ｇ
硝酸チアミン ０.０１ｇ
リン酸リボフラビンナトリウム ０.０２ｇ
塩酸ピリドキシン ０.０３ｇ
ニコチン酸アミド ０.０５ｇ
無水カフェイン ０.１０ｇ
アミノエチルスルホン酸 ２.００ｇ
ヨクイニン流エキス ２.００ｍＬ
ローヤルゼリー ０.６０ｇ
ブドウ糖 ５.００ｇ
ソルビトール ５.００ｇ
キシリトール ５.００ｇ
ステビア抽出物 ０.０２ｇ
アセスルファムカリウム ０.０３ｇ
クエン酸 ０.８０ｇ
クエン酸ナトリウム ０.１０ｇ
リン酸 ０.３０ｇ
塩酸 適量
安息香酸ナトリウム ０.０６ｇ
パラオキシ安息香酸ブチル ０.００６ｇ
パラオキシ安息香酸プロピル ０.００６ｇ
グリセリン ０.２０ｇ
ミックスフルーツフレーバー ０.１０ｇ
上記成分を精製水に溶解した後、ｐＨを３.５に調整し、精製水を加え全量を１００ｍＬとした。この液をろ紙でろ過し、滅菌装置を用いて、ろ液を８０℃で２５分間加熱滅菌した後、ガラス瓶に充填しキャップを施して内服液剤を得た。
Example 5
Zinc gluconate 0.08g
Polyglycerol fatty acid ester 0.20 g
Polyoxyethylene hydrogenated castor oil 0.10g
Tricaprylin 0.05g
Calcium gluconate 2.00g
Calcium lactate 1.00g
Sodium aspartate 0.10g
Magnesium aspartate 1.00 g
0.01 g of thiamine nitrate
Riboflavin sodium phosphate 0.02g
0.03 g of pyridoxine hydrochloride
Nicotinamide 0.05g
Anhydrous caffeine 0.10g
Aminoethylsulfonic acid 2.00g
Yokuinin style extract 2.00mL
Royal jelly 0.60g
Glucose 5.00g
Sorbitol 5.00g
Xylitol 5.00g
Stevia extract 0.02g
Acesulfame potassium 0.03g
Citric acid 0.80 g
Sodium citrate 0.10g
Phosphoric acid 0.30 g
Hydrochloric acid appropriate amount Sodium benzoate 0.06g
Butyl paraoxybenzoate 0.006g
Propyl paraoxybenzoate 0.006 g
Glycerin 0.20g
0.10g mixed fruit flavor
After dissolving the above components in purified water, the pH was adjusted to 3.5, and purified water was added to make up a total volume of 100 mL. This solution was filtered with a filter paper, and the filtrate was sterilized by heating at 80 ° C. for 25 minutes using a sterilizer, and then filled into a glass bottle and capped to obtain an internal solution.
試験例
Hagermanらは、溶液中のタンパク（ウシ血清アルブミン：ＢＳＡ）がタンニンにより凝集し、その沈澱量はタンニンの量に比例することを報告した（J.Agric.Food.Chem.,1978,Vol.26,809-812）。本発明者らは、亜鉛イオン溶液にＢＳＡ溶液を加えると、この溶液が懸濁し、吸光度が減少すること、この吸光度の減少が、亜鉛イオンの濃度に相関することを見出した。これは、ある物質を添加した亜鉛イオン溶液をＢＳＡ溶液に混合したときの吸光度が無添加の場合と比較して減少すると、その物質の添加により、タンパク−亜鉛イオン相互作用による凝集（収斂性）が減少したこと、すなわち収斂味が減少したことを意味すると考えられる。
Test example
Hagerman et al. Reported that protein (bovine serum albumin: BSA) in solution was aggregated by tannin, and the amount of precipitation was proportional to the amount of tannin ( J. Agric . Food . Chem ., 1978, Vol. 26 , 809) . -812). The present inventors have found that when a BSA solution is added to a zinc ion solution, the solution is suspended, the absorbance decreases, and this decrease in absorbance correlates with the zinc ion concentration. This is because, when the absorbance when a zinc ion solution containing a certain substance is mixed with a BSA solution decreases compared to the case where no addition is made, the addition of that substance causes aggregation due to protein-zinc ion interaction (convergence). Is considered to mean that the astringent taste has decreased.
試験方法
（１）ＢＳＡ溶液の調製：ＢＳＡ（Sigma Chemical Co.;fraction V,fatty acid free）１０ｇを適量の精製水に溶解し、クエン酸１００ｍｇを加え、ＮａＯＨ溶液（１ｍｏｌ／Ｌ）でｐＨを４.８に調整し、精製水で１００ｍＬとした。
（２）希釈液の調製：クエン酸１００ｍｇを適量の水に溶解し、ＮａＯＨ溶液（１ｍｏｌ／Ｌ）でｐＨを４.８に調整し、精製水で１００ｍＬとした。
（３）亜鉛イオン溶液の調製：グルコン酸亜鉛０.０４ｇ、０．１９及び０.３９ｇにクエン酸０.１０ｇを加えた。それぞれを適量の精製水に溶解し、ＮａＯＨ溶液（１ｍｏｌ／Ｌ）でｐＨを４.８に調整し、精製水で１００ｍＬとした。
（４）タンパク−亜鉛イオン相互作用（収斂性）の評価
各亜鉛イオン溶液２ｍＬにＢＳＡ溶液６ｍＬを加え、希釈液でそれぞれ全量を１０ｍＬとした。これを４０℃で３０分間振とうした。石英セル（Ｌ＝１ｃｍ）を使用し、分光光度計（日立製作所製：Ｕ−３３００）により、各透明溶液では吸収されない波長である５００ｎｍにおける吸光度を測定した。この結果（図１）は、亜鉛イオン濃度と吸光度が相関することを示す。
Test method
(1) Preparation of BSA solution: 10 g of BSA (Sigma Chemical Co .; fraction V, fatty acid free) is dissolved in an appropriate amount of purified water, 100 mg of citric acid is added, and pH is adjusted to 4. with NaOH solution (1 mol / L). 8 and adjusted to 100 mL with purified water.
(2) Preparation of diluting solution: 100 mg of citric acid was dissolved in an appropriate amount of water, the pH was adjusted to 4.8 with NaOH solution (1 mol / L), and adjusted to 100 mL with purified water.
(3) Preparation of zinc ion solution: 0.10 g of citric acid was added to 0.04 g, 0.19 and 0.39 g of zinc gluconate. Each was dissolved in an appropriate amount of purified water, adjusted to pH 4.8 with NaOH solution (1 mol / L), and made up to 100 mL with purified water.
(4) Evaluation of protein-zinc ion interaction (convergence)
6 mL of BSA solution was added to 2 mL of each zinc ion solution, and the total volume was adjusted to 10 mL with the diluent. This was shaken at 40 ° C. for 30 minutes. Using a quartz cell (L = 1 cm), the absorbance at 500 nm, which is a wavelength that is not absorbed by each transparent solution, was measured with a spectrophotometer (manufactured by Hitachi, Ltd .: U-3300). This result (FIG. 1) shows that the zinc ion concentration and the absorbance are correlated.
次に、各種濃度の亜鉛イオン溶液と収斂味（官能評価）との相関を調べた。官能評価は、収斂味が強くて許容できない場合をＢ、許容することができる範囲をその収斂味の強さに応じてＡ４〜Ａ１とし、収斂味を全く感じない場合をＡとして評価を行った。その結果を図２に示す。図２より、吸光度が約０．４以下であれば、亜鉛イオン由来の収斂味が十分抑制されていると判断した。 Next, the correlation between various concentrations of zinc ion solution and astringency (sensory evaluation) was examined. The sensory evaluation was evaluated as B when the astringent taste was strong and unacceptable, A4 to A1 depending on the strength of the astringent taste, and A when the astringent taste was not felt at all. . The result is shown in FIG. From FIG. 2, when the absorbance was about 0.4 or less, it was judged that the astringent taste derived from zinc ions was sufficiently suppressed.
（５）検体のタンパク凝集性
上記と同様の試験方法により、表１に示す処方のタンパク凝集性を評価した。
(5) Protein aggregation properties of specimens The protein aggregation properties of the formulations shown in Table 1 were evaluated by the same test method as described above.
表１より、ポリグリセリン脂肪酸エステルを配合した検体１および検体２の吸光度は、ポリグリセリン脂肪酸エステルを含有しない検体３よりも小さいことから、ポリグリセリン脂肪酸エステルの配合により、亜鉛イオンに由来する収斂味を低減できることが明らかとなった。 From Table 1, since the absorbance of the sample 1 and the sample 2 containing the polyglycerol fatty acid ester is smaller than that of the sample 3 not containing the polyglycerol fatty acid ester, the astringent taste derived from zinc ions is obtained by blending the polyglycerol fatty acid ester. It has become clear that can be reduced.
本発明により、亜鉛イオンに由来する収斂味を低減し、飲みやすく、しかも不快な後味が残らない亜鉛含有経口投与組成物を提供することができた。この亜鉛含有経口投与組成物は、例えば、シロップ剤、ドリンク剤などの医薬品や医薬部外品を含む各種製剤及び栄養機能食品などの各種飲料に適用できる。 According to the present invention, it is possible to provide a zinc-containing composition for oral administration that reduces the astringent taste derived from zinc ions, is easy to drink, and does not leave an unpleasant aftertaste. This zinc-containing oral administration composition can be applied, for example, to various preparations including pharmaceuticals such as syrups and drinks and quasi-drugs, and various beverages such as nutritional functional foods.
Claims (5)
A method for reducing an unpleasant taste of an orally administered composition containing a zinc compound, comprising blending a polyglycerol fatty acid ester.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005196925A JP4929629B2 (en) | 2004-07-08 | 2005-07-06 | Zinc-containing composition for oral administration |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004201259 | 2004-07-08 | ||
| JP2004201259 | 2004-07-08 | ||
| JP2005196925A JP4929629B2 (en) | 2004-07-08 | 2005-07-06 | Zinc-containing composition for oral administration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006045217A true JP2006045217A (en) | 2006-02-16 |
| JP4929629B2 JP4929629B2 (en) | 2012-05-09 |
Family
ID=36024208
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005196925A Expired - Fee Related JP4929629B2 (en) | 2004-07-08 | 2005-07-06 | Zinc-containing composition for oral administration |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP4929629B2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008182948A (en) * | 2007-01-30 | 2008-08-14 | Goshu Yakuhin Kk | Zinc-containing drink |
| US8399014B2 (en) | 2008-12-24 | 2013-03-19 | Maruha Nichiro Foods, Inc. | Physiologically active complex comprising protamine and/or salt therefor and an acidic macromolecular substance, and use thereof |
| WO2019054859A1 (en) * | 2017-09-12 | 2019-03-21 | Purac Biochem B.V. | Meat treatment |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09238645A (en) * | 1996-03-08 | 1997-09-16 | Meiji Milk Prod Co Ltd | Method for preventing precipitation of insoluble calcium and improving taste of liquid food |
| JPH09323931A (en) * | 1996-06-04 | 1997-12-16 | Taisho Pharmaceut Co Ltd | Liquid medicine composition combined with loperamide hydrochloride |
| JPH09328429A (en) * | 1996-06-07 | 1997-12-22 | Taisho Pharmaceut Co Ltd | Liquid preparation composition formulated with vitamin b1 derivative |
| JP2000060488A (en) * | 1998-08-25 | 2000-02-29 | Taiyo Kagaku Co Ltd | Mineral composition |
| JP2000157213A (en) * | 1998-11-26 | 2000-06-13 | Morinaga Milk Ind Co Ltd | Nourishing composition |
| JP2000157214A (en) * | 1998-12-01 | 2000-06-13 | Taiyo Kagaku Co Ltd | Neutralized salt-generating mineral composition |
| JP2000201648A (en) * | 1998-11-12 | 2000-07-25 | Otsuka Pharmaceut Factory Inc | Nutritious composition and liquid food |
| JP2001061443A (en) * | 1999-08-25 | 2001-03-13 | Snow Brand Milk Prod Co Ltd | Finely dispersed mineral liquid and its production |
| JP2002080347A (en) * | 2000-09-04 | 2002-03-19 | Taisho Pharmaceut Co Ltd | Oral liquid medicine formulated with iron compound |
| JP2002142720A (en) * | 2000-11-08 | 2002-05-21 | Otsuka Pharmaceut Factory Inc | Nutritional composition |
| JP2003073284A (en) * | 2001-06-22 | 2003-03-12 | Taisho Pharmaceut Co Ltd | Liquid composition |
| JP2003137755A (en) * | 2001-11-02 | 2003-05-14 | Lion Corp | Composition for oral cavity |
| JP2004224778A (en) * | 2003-01-27 | 2004-08-12 | Kao Corp | Composition for oral cavity |
| WO2005004640A1 (en) * | 2003-07-10 | 2005-01-20 | Taiyo Kagaku Co., Ltd. | Mineral composition |
-
2005
- 2005-07-06 JP JP2005196925A patent/JP4929629B2/en not_active Expired - Fee Related
Patent Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09238645A (en) * | 1996-03-08 | 1997-09-16 | Meiji Milk Prod Co Ltd | Method for preventing precipitation of insoluble calcium and improving taste of liquid food |
| JPH09323931A (en) * | 1996-06-04 | 1997-12-16 | Taisho Pharmaceut Co Ltd | Liquid medicine composition combined with loperamide hydrochloride |
| JPH09328429A (en) * | 1996-06-07 | 1997-12-22 | Taisho Pharmaceut Co Ltd | Liquid preparation composition formulated with vitamin b1 derivative |
| JP2000060488A (en) * | 1998-08-25 | 2000-02-29 | Taiyo Kagaku Co Ltd | Mineral composition |
| JP2000201648A (en) * | 1998-11-12 | 2000-07-25 | Otsuka Pharmaceut Factory Inc | Nutritious composition and liquid food |
| JP2000157213A (en) * | 1998-11-26 | 2000-06-13 | Morinaga Milk Ind Co Ltd | Nourishing composition |
| JP2000157214A (en) * | 1998-12-01 | 2000-06-13 | Taiyo Kagaku Co Ltd | Neutralized salt-generating mineral composition |
| JP2001061443A (en) * | 1999-08-25 | 2001-03-13 | Snow Brand Milk Prod Co Ltd | Finely dispersed mineral liquid and its production |
| JP2002080347A (en) * | 2000-09-04 | 2002-03-19 | Taisho Pharmaceut Co Ltd | Oral liquid medicine formulated with iron compound |
| JP2002142720A (en) * | 2000-11-08 | 2002-05-21 | Otsuka Pharmaceut Factory Inc | Nutritional composition |
| JP2003073284A (en) * | 2001-06-22 | 2003-03-12 | Taisho Pharmaceut Co Ltd | Liquid composition |
| JP2003137755A (en) * | 2001-11-02 | 2003-05-14 | Lion Corp | Composition for oral cavity |
| JP2004224778A (en) * | 2003-01-27 | 2004-08-12 | Kao Corp | Composition for oral cavity |
| WO2005004640A1 (en) * | 2003-07-10 | 2005-01-20 | Taiyo Kagaku Co., Ltd. | Mineral composition |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008182948A (en) * | 2007-01-30 | 2008-08-14 | Goshu Yakuhin Kk | Zinc-containing drink |
| US8399014B2 (en) | 2008-12-24 | 2013-03-19 | Maruha Nichiro Foods, Inc. | Physiologically active complex comprising protamine and/or salt therefor and an acidic macromolecular substance, and use thereof |
| WO2019054859A1 (en) * | 2017-09-12 | 2019-03-21 | Purac Biochem B.V. | Meat treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| JP4929629B2 (en) | 2012-05-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5162812B2 (en) | Zinc-containing composition for oral administration | |
| JP4337308B2 (en) | Liquid composition | |
| JP5586816B2 (en) | Composition containing zinc compound | |
| JP4929629B2 (en) | Zinc-containing composition for oral administration | |
| JP5295571B2 (en) | Solution for internal use for fatigue recovery | |
| JP5098198B2 (en) | Copper compound composition | |
| JP4929628B2 (en) | Zinc-containing oral solution | |
| JP5044957B2 (en) | Copper compound composition | |
| JP5546089B2 (en) | Composition containing zinc compound | |
| JP5167594B2 (en) | Composition for internal use liquid containing copper compound | |
| JP4742289B2 (en) | Solubilized liquid composition with herbal medicine | |
| JP5398100B2 (en) | Oral liquid composition containing iron compound | |
| JP5151083B2 (en) | Oral composition | |
| JP5181486B2 (en) | Oral composition containing zinc compound | |
| JP4929589B2 (en) | Copper-containing oral administration composition | |
| JP2007246509A (en) | Oral composition compounded with copper compound | |
| JP2004315439A (en) | Liquid composition for internal use containing iron compound | |
| JP4403595B2 (en) | Iron compound-containing oral solution composition | |
| JP5011776B2 (en) | Copper compound composition | |
| JP4216916B2 (en) | Drinking liquid composition | |
| JP4586336B2 (en) | Aqueous solution containing fat-soluble substances | |
| JP4815798B2 (en) | Copper-containing composition for oral administration | |
| JP2004315441A (en) | Liquid composition for internal use containing iron compound | |
| JP2005255653A (en) | Internal liquid medicine formulated with iron compound | |
| JP2005087144A (en) | Liquid composition compounded with ginseng |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080528 |
|
| RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110308 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110428 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111101 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111219 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120117 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120130 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 4929629 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150224 Year of fee payment: 3 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150224 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |